View Older Stories View More Recent Stories

Mar 30, 2020 08:00AM Daré Bioscience Reports 2019 Financial Results and Provides a Company Update
Mar 24, 2020 08:00AM Daré Bioscience to Host Fourth Quarter and Full-year 2019 Financial Results and Company Update Conference Call and Webcast on March 30, 2020
Mar 10, 2020 08:14AM Dare Bioscience (DARE) Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis
Mar 10, 2020 08:00AM Daré Bioscience Receives FDA Fast Track Designation for DARE-BV1 for the Treatment of Bacterial Vaginosis
Mar 9, 2020 08:08AM Dare Bioscience (DARE) Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder
Mar 9, 2020 08:00AM Daré Bioscience Presents Positive Sildenafil Cream, 3.6% Data Supporting Further Development for the Treatment of Female Sexual Arousal Disorder
Feb 27, 2020 08:00AM Daré Bioscience to Present at the Cowen 40th Annual Health Care Conference
Feb 6, 2020 08:19AM Dare Bioscience (DARE) Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Feb 6, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Feb 6, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Feb 6, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Equity Rule and Secures Capital to Advance Product Candidates
Feb 5, 2020 08:00AM Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference
Feb 5, 2020 08:00AM Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference
Feb 5, 2020 08:00AM Daré Bioscience to Present at the 2020 BIO CEO & Investor Conference
Jan 30, 2020 08:05AM Dare Bioscience (DARE) Regains Compliance with Nasdaq Minimum Bid Price Rule
Jan 30, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Jan 30, 2020 08:00AM Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule
Jan 15, 2020 08:00AM Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update
Jan 15, 2020 08:00AM Daré Bioscience Schedules Conference Call for January 22, 2020 to Discuss Ovaprene® Licensing Agreement and General Corporate Update
Dec 18, 2019 08:07AM Dare Bioscience (DARE) Reports FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study
Dec 18, 2019 08:00AM Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study
Dec 18, 2019 08:00AM Daré Bioscience Announces FDA Clearance of IND Application for DARE-BV1 for Bacterial Vaginosis to Commence Pivotal Phase 3 Clinical Study
Dec 11, 2019 08:07AM Dare Bio (DARE) Announces Alignment with FDA on Phase 2b Study Design, Primary Endpoint PRO Instruments to Support Development of Sildenafil Cream, 3.6%, for Female Sexual Arousal Disorder
Dec 11, 2019 08:00AM Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potenti
Dec 11, 2019 08:00AM Daré Bioscience Announces Alignment with the FDA on Phase 2b Study Design and Novel Primary Endpoint PRO Instruments to Support the Continued Clinical Development of Sildenafil Cream, 3.6%, a Potenti
Dec 10, 2019 08:00AM Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems
Dec 10, 2019 08:00AM Daré Bioscience Announces Feature Presentation at the15th US-Japan Symposium on Drug Delivery Systems
Nov 21, 2019 08:00AM Daré Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform
Nov 14, 2019 08:00AM Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update
Nov 14, 2019 08:00AM Daré Bioscience Reports Third Quarter 2019 Financial Results and Provides Company Update
Nov 12, 2019 08:00AM Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate
Nov 12, 2019 08:00AM Daré Bioscience Announces Positive Findings from a Postcoital Test Clinical Study of Ovaprene® Hormone-Free Contraceptive Candidate
Nov 11, 2019 08:07AM Dare Bioscience (DARE) Reports Acquisition of Microchips Biotech Inc.
Nov 11, 2019 08:00AM Daré Bioscience Enters into Agreement to Acquire Microchips Biotech Including Its First-in-Class Wireless, User-Controlled Drug Delivery Platform
Nov 7, 2019 08:30AM Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast
Nov 7, 2019 08:30AM Daré Bioscience to Host Third Quarter 2019 Financial Results and Company Update Conference Call and Webcast
Oct 31, 2019 08:00AM Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360
Oct 31, 2019 08:00AM Daré Bioscience Announces Presentation of Two Posters at American Association of Pharmaceutical Scientists 2019 PharmSci 360
Oct 28, 2019 08:00AM Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine Soc
Oct 28, 2019 08:00AM Daré Bioscience and Strategic Science & Technologies Announce Presentation of Positive Findings from Thermography Clinical Study of Sildenafil Cream, 3.6 % in Healthy Women at the Sexual Medicine
Oct 10, 2019 08:01AM Dare Bioscience (DARE) Announces Poster Presentation on Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance
Oct 10, 2019 08:00AM Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society f
Oct 10, 2019 08:00AM Daré Bioscience Announces a Poster Presentation on a Pharmacokinetic Study of DARE-FRT1, in Development for Sustained-Release Progesterone Therapy for Pregnancy Maintenance, at the American Society f
Oct 7, 2019 08:00AM Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportuni
Oct 7, 2019 08:00AM Daré Bioscience to Present an Overview on its Intravaginal Ring (IVR) Technology in Development for Sustained-Release Hormone Therapy and Pregnancy Maintenance at the 9th Annual Partnership Opportuni
Sep 4, 2019 08:00AM Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Sep 4, 2019 08:00AM Daré Bioscience to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Aug 14, 2019 04:01PM Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update
Aug 14, 2019 04:01PM Daré Bioscience Reports Second Quarter 2019 Financial Results and Company Update
Aug 6, 2019 08:00AM Daré Bioscience to Host Second Quarter 2019 Financial Results and Company Update Conference Call and Webcast
View More Recent Stories View Older Stories